Clinical-stage biotech firm COUR Pharmaceuticals announced a strategic partnership and licensing agreement with Genentech, a Roche subsidiary, for the development and commercialization of COUR's proprietary tolerogenic nanoparticle treatments for an undisclosed autoimmune disease.
Under the agreement with Genentech, COUR is responsible for the preclinical development and technical transfer of manufacturing, COUR said in a statement. Genentech is responsible for clinical development, regulatory filing, and commercialization of the treatments developed.
COUR is eligible for upfront and near-term milestones of $40 million, it said. Additional development, commercial, and net sales milestone payments could exceed $900 million, according to COUR; the agreement also includes tiered royalties on net sales.
COUR's therapies, based on a proprietary platform, are designed to induce antigen-specific tolerance for immune-mediated diseases.
